Brief: Arrowhead Pharmaceuticals Announces Interim Clinical Data On Rnai-Based Obesity Candidates
06/01/2026 12:47
Jan 6 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O: ARROWHEAD PHARMACEUTICALS ANNOUNCES INTERIM CLINICAL DATA ON RNAI-BASED OBESITY CANDIDATES SHOWING WEIGHT LOSS IN OBESE PATIENTS WITH DIABETES AND IMPROVED MEASURES OF BODY COMPOSITION ARROWHEAD PHARMACEUTICALS - ARO-INHBE WITH TIRZEPATIDE ACHIEVES -9.4% WEIGHT LOSS ARROWHEAD PHARMACEUTICALS - ARO-INHBE MONOTHERAPY ACHIEVES -9.9% VISCERAL FAT REDUCTION ARROWHEAD PHARMACEUTICALS - ARO-ALK7 ACHIEVES -88% REDUCTION IN ALK7 MRNA Source text: ID:nBw1w8zvQa Further company coverage: ARWR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers